Literature DB >> 32560962

Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Diana O Perkins1, Clark D Jeffries2, Kim Q Do3.   

Abstract

Converging evidence implicates redox dysregulation as a pathological mechanism driving the emergence of psychosis. Increased oxidative damage and decreased capacity of intracellular redox modulatory systems are consistent findings in persons with schizophrenia as well as in persons at clinical high risk who subsequently developed frank psychosis. Levels of glutathione, a key regulator of cellular redox status, are reduced in the medial prefrontal cortex, striatum, and thalamus in schizophrenia. In humans with schizophrenia and in rodent models recapitulating various features of schizophrenia, redox dysregulation is linked to reductions of parvalbumin containing gamma-aminobutyric acid (GABA) interneurons and volumes of their perineuronal nets, white matter abnormalities, and microglia activation. Importantly, the activity of transcription factors, kinases, and phosphatases regulating diverse aspects of neurodevelopment and synaptic plasticity varies according to cellular redox state. Molecules regulating interneuron function under redox control include NMDA receptor subunits GluN1 and GluN2A as well as KEAP1 (regulator of transcription factor NRF2). In a rodent schizophrenia model characterized by impaired glutathione synthesis, the Gclm knockout mouse, oxidative stress activated MMP9 (matrix metalloprotease 9) via its redox-responsive regulatory sites, causing a cascade of molecular events leading to microglia activation, perineural net degradation, and impaired NMDA receptor function. Molecular pathways under redox control are implicated in the etiopathology of schizophrenia and are attractive drug targets for individualized drug therapy trials in the contexts of prevention and treatment of psychosis.
Copyright © 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical high risk; Gclm KO; Glutathione; Grin2A KO; MMP9; Oxidative stress; Psychosis; Redox; Schizophrenia

Mesh:

Substances:

Year:  2020        PMID: 32560962      PMCID: PMC7395886          DOI: 10.1016/j.biopsych.2020.03.016

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  147 in total

1.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

Authors:  K Q Do; A H Trabesinger; M Kirsten-Krüger; C J Lauer; U Dydak; D Hell; F Holsboer; P Boesiger; M Cuénod
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

2.  Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: Pilot study.

Authors:  Chrysa Retsa; Jean-François Knebel; Eveline Geiser; Carina Ferrari; Raoul Jenni; Margot Fournier; Luis Alameda; Philipp S Baumann; Stephanie Clarke; Philippe Conus; Kim Q Do; Micah M Murray
Journal:  Schizophr Res       Date:  2017-07-12       Impact factor: 4.939

3.  Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: Study of sex differences and brain oxidative alterations.

Authors:  Aline Santos Monte; Bruna Stefânia Ferreira Mello; Vládia Célia Moreira Borella; Tatiane da Silva Araujo; Francisco Eliclécio Rodrigues da Silva; Francisca Cléa F de Sousa; Antônio Carlos Pinheiro de Oliveira; Clarissa Severino Gama; Mary V Seeman; Silvânia Maria Mendes Vasconcelos; David Freitas De Lucena; Danielle Macêdo
Journal:  Behav Brain Res       Date:  2017-05-17       Impact factor: 3.332

4.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

5.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

6.  Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction.

Authors:  Lauren Kosten; Jeroen Verhaeghe; Robert Verkerk; David Thomae; Livia De Picker; Leonie Wyffels; Annemie Van Eetveldt; Stefanie Dedeurwaerdere; Sigrid Stroobants; Steven Staelens
Journal:  Psychiatry Res Neuroimaging       Date:  2016-01-12       Impact factor: 2.376

Review 7.  Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation.

Authors:  Stuart A Lipton; Yun-Beom Choi; Hiroto Takahashi; Dongxian Zhang; Weizhong Li; Adam Godzik; Laurie A Bankston
Journal:  Trends Neurosci       Date:  2002-09       Impact factor: 13.837

8.  A lack of GluN2A-containing NMDA receptors confers a vulnerability to redox dysregulation: Consequences on parvalbumin interneurons, and their perineuronal nets.

Authors:  Romain Cardis; Jan-Harry Cabungcal; Daniella Dwir; Kim Q Do; Pascal Steullet
Journal:  Neurobiol Dis       Date:  2017-10-10       Impact factor: 5.996

Review 9.  Interneurons. Fast-spiking, parvalbumin⁺ GABAergic interneurons: from cellular design to microcircuit function.

Authors:  Hua Hu; Jian Gan; Peter Jonas
Journal:  Science       Date:  2014-07-31       Impact factor: 47.728

10.  Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system.

Authors:  Paul S Baxter; Karen F S Bell; Philip Hasel; Angela M Kaindl; Michael Fricker; Derek Thomson; Sean P Cregan; Thomas H Gillingwater; Giles E Hardingham
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

View more
  20 in total

Review 1.  Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity.

Authors:  Sophia Vinogradov; Matthew V Chafee; Erik Lee; Hirofumi Morishita
Journal:  Neuropsychopharmacology       Date:  2022-09-30       Impact factor: 8.294

2.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 3.  Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.

Authors:  Felipe V Gomes; Anthony A Grace
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 4.  Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia.

Authors:  Michel Cuenod; Pascal Steullet; Jan-Harry Cabungcal; Daniella Dwir; Ines Khadimallah; Paul Klauser; Philippe Conus; Kim Q Do
Journal:  Mol Psychiatry       Date:  2021-11-10       Impact factor: 13.437

Review 5.  Are CB2 Receptors a New Target for Schizophrenia Treatment?

Authors:  Isadora L Cortez; Naielly Rodrigues da Silva; Francisco S Guimarães; Felipe V Gomes
Journal:  Front Psychiatry       Date:  2020-10-30       Impact factor: 4.157

Review 6.  Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Authors:  Evgeny A Ermakov; Elena M Dmitrieva; Daria A Parshukova; Daria V Kazantseva; Alisa R Vasilieva; Liudmila P Smirnova
Journal:  Oxid Med Cell Longev       Date:  2021-01-23       Impact factor: 6.543

7.  Counteracting Effects of Glutathione on the Glutamate-Driven Excitation/Inhibition Imbalance in First-Episode Schizophrenia: A 7T MRS and Dynamic Causal Modeling Study.

Authors:  Roberto Limongi; Peter Jeon; Jean Théberge; Lena Palaniyappan
Journal:  Antioxidants (Basel)       Date:  2021-01-08

8.  Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study.

Authors:  Xi Rong Li; Mei Hong Xiu; Xiao Ni Guan; Yue Chan Wang; Jun Wang; Edison Leung; Xiang Yang Zhang
Journal:  Neurotherapeutics       Date:  2021-03-31       Impact factor: 7.620

Review 9.  Oxidative Dysregulation in Early Life Stress and Posttraumatic Stress Disorder: A Comprehensive Review.

Authors:  Evangelos Karanikas; Nikolaos P Daskalakis; Agorastos Agorastos
Journal:  Brain Sci       Date:  2021-05-29

10.  Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague-Dawley Rats.

Authors:  Marta Anna Lech; Monika Leśkiewicz; Kinga Kamińska; Zofia Rogóż; Elżbieta Lorenc-Koci
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.